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Votre Abstract: Introduction : Graft-versus-host disease (GVHD) has remained one of the major complication of
allogeneic hematopoietic stem cell transplantation (HSCT) for the last decades. Following unmanipulated peripheral-
blood stem cell transplantation, 60% of the patients experience chronic GVHD while approximately 15% of them develop
a sclerodermic form of chronic GVHD  characterized by multiple organ fibrosis and loss of skin elasticity. Regulatory T
cells (Tregs) play a pivotal protective role in the pathogenesis of chronic GVHD by inhibiting alloreactive conventional T
cells (Tconvs). Several studies have shown that hypomethylating agents such as azacytidine (Aza) can demethylate the
master transcription factor of Treg (Forkhead box protein 3 factor, FoxP3), thus promoting Treg differentiation from
Tconvs. This work investigates the impact of Aza in a classical murine model of sclerodermic chronic graft-versus-host
disease (B10.D2 - BALB/cJ).
 
Methods  :  In  vitro  analyses  have  been  performed  to  determine  the  impact  of  Aza  on  collagen  production.  NIH-3T3
fibroblastic  cells  were  plated  and  stimulated  with  50  ng  of  PDGF  or  10  ng  of  TGF-beta.  Cells  were  then  cultured  with
various  concentrations  of  Azacytidine  for  48  hours.  After  culture,  cells  were  washed  and  then  stained  with  Sirius  Red
before quantification of collagen amount by absorbance at 490 nm. Concerning in vivo experiments, lethally irradiated (7
Gy) BALB/cJ recipient mice were injected with 10.106 bone marrow cells + 70.106 splenocytes from B10.D2 donor mice to
induce sclerodermic  chronic  graft-versus-host  disease.  Following tranplantation,  recipient  mice were injected with  either
0,5 or 2 mg/kg of Aza every 48 hours from day 10 to 30 following transplantation. GVHD severity was scored using a five
criteria  scale  (weight  loss,  activity,  fibrosis,  hair  loss  and  mice  posture;  0-1-2  points/criteria).  Mice  were  sacrificed  at  a
score of 8/10 (or > 20% weight loss) or at day 52 after transplantation (end of experiment).
 
Results : Concerning in vitro analyses, results suggest a decreased production of collagen at higher concentration of Aza
with both stimulations by TGF-beta or PDGF (seen by a gradual diminution of absorbance). For in vivo experiments, mice
treated with Aza 0.5 mg/kg (n = 14) or 2 mg/kg (n = 25) had significant lower clinical scores of GVHD compared to control
ones (n = 23) after the end of the treatment. FACS analysis showed a higher proportion of Treg among CD4+ T cells in
the blood of Aza 2 mg/kg mice than in control  mice at  day 35 following transplantation (P = 0.047),  as well  as a higher
percentage of Tregs expressing the KI67 proliferative marker at the same time point (P = 0.0005). Finally, analyses of the
cellular blood components with Cell-dyn demonstrated that Aza 2 mg/kg treated mice were significantly lymphopenic as
compared to control mice at day 35 after transplantation (P = 0.05).
 
Conclusion : Aza prevented sclerodermic GVHD in this classical murine model of chronic GVHD.
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